Silverberg Bernstein Capital Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$569K Sell
38,980
-1,700
-4% -$16.4K 0.22% 45
2026
Q1
$302K Sell
40,680
-700
-2% -$7.37K 0.17% 58
2025
Q4
$487K Sell
41,380
-3,200
-7% -$34.5K 0.28% 48
2025
Q3
$344K Buy
44,580
+4,200
+10% +$29.4K 0.21% 51
2025
Q2
$295K Buy
40,380
+19,300
+92% +$156K 0.2% 53
2025
Q1
$200K Sell
21,080
-100
-0.5% -$1.25K 0.19% 55
2024
Q4
$349K Sell
21,180
-4,000
-16% -$62.1K 0.31% 40
2024
Q3
$371K Hold
25,180
0.34% 39
2024
Q2
$349K Hold
25,180
0.34% 39
2024
Q1
$396K Sell
25,180
-3,000
-11% -$46.3K 0.39% 38
2023
Q4
$456K Buy
+28,180
New +$461K 0.44% 36

Other funds holding NEO

Silverberg Bernstein Capital Management's NEO Position: Q2 2026 in Review

Silverberg Bernstein Capital Management reduced its NeoGenomics (NEO) stake by 4.2% in Q2 2026, selling an estimated $16.4K and leaving 38,980 shares worth $569K. The position accounts for 0.22% of the portfolio, ranked #45.

Silverberg Bernstein Capital Management first reported a position in NEO in Q4 2023 and has held it in 11 quarters since. 54 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • Silverberg Bernstein Capital Management held 38,980 shares of NeoGenomics worth $569K as of Q2 2026.
  • Silverberg Bernstein Capital Management sold 1,700 NeoGenomics shares in Q2 2026, an estimated $16.4K.
  • NeoGenomics made up 0.22% of Silverberg Bernstein Capital Management's portfolio in Q2 2026, its #45 holding.
  • Silverberg Bernstein Capital Management first reported a position in NeoGenomics in Q4 2023 and has held it in 11 quarters since.
  • 54 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on Silverberg Bernstein Capital Management's 13F filing for Q2 2026, filed 7 Jul 2026.